Medications

Benefits of valoctocogene roxaparvovec persist in hemophilia A

For patients with hemophilia A, factor VIII activity and bleeding reduction persist at two years after gene transfer with valoctocogene roxaparvovec, which delivers a B-domain-deleted factor VIII coding sequence with an adeno-associated ...

page 1 from 7